ADMA Biologics Reports Updated IVIG Process Study Results
ADMA Biologics says a three-lot study found its updated IVIG process removed clot-linked impurities and raised yield. No clotting events were reported through July 2026.
ADMA Biologics says a three-lot study found its updated IVIG process removed clot-linked impurities and raised yield. No clotting events were reported through July 2026.